Perrigo Company plc Income Tax Examination, Interest Expense
Perrigo Company plc (PRGO) had Income Tax Examination, Interest Expense of $348.20 million as of 2025-03-12, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:IncomeTaxExaminationInterestExpense · last filed 2026-08-05
- 2025-03-12: Income Tax Examination, Interest Expense $348.20M.
- 2023-05-05: Income Tax Examination, Interest Expense $153.40M.
| Period end | Income Tax Examination, Interest Expense |
|---|---|
| 2025-03-12 | $348.20M 10-Q · filed 2026-08-05 |
| 2023-05-05 | $153.40M 10-Q · filed 2024-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |